Evidence map›Paper›PMID 30191630›Full record

ArticleCancer science2018

FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells.

Ming-Min Chang, Meng-Shao Lai, Siou-Ying Hong, Bo-Syong Pan, Hsin Huang, Shang-Hsun Yang, Chia-Ching Wu, H Sunny Sun, Jih-Ing Chuang, Chia-Yih Wang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Ming-Min ChangDepartment of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.ORCID http://orcid.org/0000-0002-6537-2249
Meng-Shao LaiDepartment of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Siou-Ying HongDepartment of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Bo-Syong PanDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC, USA.
Hsin HuangDepartment of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Shang-Hsun YangDepartment of Basic Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chia-Ching WuDepartment of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
H Sunny SunDepartment of Basic Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Jih-Ing ChuangDepartment of Basic Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chia-Yih WangDepartment of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Bu-Miin HuangDepartment of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
National Cheng Kung University · TWChina Medical University · TWWake Forest University · US

Funding

Ministry of Science and Technology, Taiwan MOST104-2320-B-006-041Ministry of Science and Technology, Taiwan MOST105-2320-B-006-001Ministry of Science and Technology, Taiwan MOST105-2320-B-006-028-MY3Ministry of Science and Technology, Taiwan MOST105-2811-B-006-056Ministry of Science and Technology, Taiwan MOST106-2320-B-006-001Ministry of Science and Technology, Taiwan MOST106-2320-B-006-003Ministry of Science and Technology, Taiwan MOST106-2811-B-006-014Ministry of Science and Technology, Taiwan MOST107-2811-B-006-519
6 · The paper itself

Abstract

Fibroblast growth factor 9 (FGF9) promotes cancer progression; however, its role in cell proliferation related to tumorigenesis remains elusive. We investigated how FGF9 affected MA-10 mouse Leydig tumor cell proliferation and found that FGF9 significantly induced cell proliferation by activating ERK1/2 and retinoblastoma (Rb) phosphorylations within 15 minutes. Subsequently, the expressions of E2F1 and the cell cycle regulators: cyclin D1, cyclin E1 and cyclin-dependent kinase 4 (CDK4) in G

Indexed as

AnimalsCell CycleCell Line, TumorCell ProliferationE2F1 Transcription FactorExtracellular Signal-Regulated MAP KinasesFibroblast Growth Factor 9Gene Expression Regulation, NeoplasticLeydig Cell TumorMaleMicePhosphorylationReceptor, Fibroblast Growth Factor, Type 2Retinoblastoma ProteinSignal TransductionTesticular NeoplasmsE2f1 protein, mouseE2F1 Transcription FactorExtracellular Signal-Regulated MAP KinasesFgf9 protein, mouseFgfr2 protein, mouseFibroblast Growth Factor 9Receptor, Fibroblast Growth Factor, Type 2Retinoblastoma ProteinERK1/2FGF9FGFR2MA-10 Leydig tumor cell proliferationRb/E2F1

Identifiers

PMID30191630
PMCPMC6215879
OpenAlexW2891508711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.